Sudan virus like Marburg virus is a member of the Filoviridae family, but of the divergent Ebolavirus genus. Sudan ebolavirus (SUDV) is one of six distinct species of ebolavirus that includes Zaire (Ebola), Bundibugyo, Tai Forest, Reston and the recently discovered Bombali ebolaviruses. Only four are known to cause disease in humans, Sudan, Zaire, Bundibugyo and Tai Forest. Discovered in the Sudan in 1976, SUDV has caused eight outbreaks in equatorial Africa resulting in nearly 800 infected individuals and 400 deaths, the most recent in 2012 in Uganda.
SUDV can cause severe hemorrhagic fever in humans and nonhuman primates with an approximate 50% mortality rate. Filoviruses are zoonotic having natural reservoirs with life cycles in non-human animals allowing transmission to humans. Once in humans, transmission occurs through close contact with an infected individual or their body fluids. Like other human pathogenic ebolaviruses, SUDV has the potential to emerge in outbreaks that may result in epidemics, although documented outbreaks have involved relatively small numbers (1-500).
PHV‘s SUDV vaccine candidate is also generated on the proven rVSV platform, like it’s other programs and the successful licensed Ebola (Zaire) vaccine named Ervebo®. The vaccine virus rVSV∆G-SUDV GP, has been constructed by the National Microbiology Laboratory of the Public Health Agency of Canada, and mirrors the MARV vaccine and the Ebola vaccine using the same platform technology.